Wanbangde Pharmaceutical Holding Group (002082.SZ): WP103 drug receives new drug clinical trial approval from the US FDA.

Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Holding Group Pharmaceutical Group Co., Ltd., received a notification from the U.S. Food and Drug Administration (FDA) on January 17, 2025. The company's independently developed WP103 (methylisoquinolinone injection) for the treatment of "neonatal hypoxic-ischemic encephalopathy" clinical trial application has been granted permission.